Cargando…

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers

The aggregation of α-synuclein (α-syn) into neurotoxic oligomers and fibrils is an important pathogenic feature of synucleinopatheis, including Parkinson’s disease (PD). A further characteristic of PD is the oxidative stress that results in the formation of aldehydes by lipid peroxidation. It has be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaikath, Nishant, Sudhakaran, Indulekha, Abdi, Ilham, Gupta, Vijay, Majbour, Nour, Ghanem, Simona, Abdesselem, Houari, Vekrellis, Kostas, El-Agnaf, Omar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740078/ https://www.ncbi.nlm.nih.gov/pubmed/36498957 http://dx.doi.org/10.3390/ijms232314630

Ejemplares similares

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit in‐vitro seeded aggregation and toxicity
por: Hmila, Issam, et al.
Publicado: (2022)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies
por: Gupta, Vijay, et al.
Publicado: (2020)

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice
por: Karampetsou, Mantia, et al.
Publicado: (2017)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts
por: Ardah, Mustafa T., et al.
Publicado: (2020)

Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
por: Ghanem, Simona S., et al.
Publicado: (2021)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
por: Anagnostou, Dimitrios, et al.
Publicado: (2023)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

Screening for Novel Inhibitors of Amyloid Beta Aggregation and Toxicity as Potential Drugs for Alzheimer’s Disease
por: Sharari, Sanaa, et al.
Publicado: (2023)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

Uncovering a neurological protein signature for severe COVID-19
por: El-Agnaf, Omar, et al.
Publicado: (2023)

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
por: Landeck, Natalie, et al.
Publicado: (2016)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Lighting Up Alpha-synuclein Oligomers
por: Richter, Franziska
Publicado: (2018)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy
por: Wu, Jia-Zhen, et al.
Publicado: (2019)

In silico modeling of the effects of alpha-synuclein oligomerization on dopaminergic neuronal homeostasis
por: Ouzounoglou, Eleftherios, et al.
Publicado: (2014)

Direct detection of alpha synuclein oligomers in vivo
por: Dimant, Hemi, et al.
Publicado: (2013)

Alpha-synuclein oligomers: a new hope
por: Bengoa-Vergniory, Nora, et al.
Publicado: (2017)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species
por: Pampalakis, Georgios, et al.
Publicado: (2016)

Exosomal cell-to-cell transmission of alpha synuclein oligomers
por: Danzer, Karin M, et al.
Publicado: (2012)

Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson’s Disease
por: Leandrou, Emmanouela, et al.
Publicado: (2019)

Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes
por: Gustafsson, Gabriel, et al.
Publicado: (2017)

Intrastriatal Administration of Exosome-Associated Pathological Alpha-Synuclein Is Not Sufficient by Itself to Cause Pathology Transmission
por: Karampetsou, Mantia, et al.
Publicado: (2020)

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
por: Oliveira, Luis M. A., et al.
Publicado: (2021)

RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation
por: Oueslati, Abid, et al.
Publicado: (2014)

Temperature-Dependent Structural Changes of Parkinson's Alpha-Synuclein Reveal the Role of Pre-Existing Oligomers in Alpha-Synuclein Fibrillization
por: Ariesandi, Winny, et al.
Publicado: (2013)

Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans
por: Chen, Kevin S., et al.
Publicado: (2021)

Mutation of Tyrosine Sites in the Human Alpha-Synuclein Gene Induces Neurotoxicity in Transgenic Mice with Soluble Alpha-Synuclein Oligomer Formation
por: Lassen, Louise Berkhoudt, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1kainj40p8997vg2p78gh35o1s